DoD Duchenne Muscular Dystrophy, Idea Development Award | W81XWH 21 DMDRP IDA

Frequently Asked Questions (FAQs)

What is the Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award?

The DMDRP Idea Development Award (Funding Opportunity Number W81XWH-21-DMDRP-IDA) is a Department of Defense funding mechanism offered through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It supports early-stage, conceptually bold research intended to improve outcomes for people living with Duchenne muscular dystrophy (DMD).

What is the main purpose of this award?

The core purpose is to help investigators generate impactful new data and open new lines of inquiry in DMD, particularly when the work is still in an idea-forming or proof-of-concept phase. The program aims to catalyze research directions that could reshape what is possible in DMD research.

What kinds of projects are a good fit for this opportunity?

Projects are expected to be high-risk/high-reward, potentially challenging conventional thinking or pursuing unconventional approaches. At the same time, proposed work must be grounded in a strong scientific rationale and built around a well-formulated, testable hypothesis.

Is this award intended to fund incremental extensions of existing research?

No. The opportunity emphasizes innovation and impact and is described as not intended for incremental extensions of established work. It is meant to catalyze ideas that could change the trajectory of the DMD field.

How does the program define or emphasize innovation?

On the innovation side, the program looks for research that introduces new paradigms, questions existing assumptions, reframes persistent problems from new angles, or otherwise demonstrates uniquely creative thinking.

How does the program define or emphasize impact?

On the impact side, applications should make a credible case that, if successful, the research could drive major advances and meaningfully accelerate progress toward better clinical or functional outcomes in DMD.

Do applicants need preliminary data?

Yes. Even though the award supports early-stage concepts, it is not designed for projects with no supporting evidence. Applicants are required to include preliminary data relevant to DMD to help demonstrate feasibility of both the hypothesis and the proposed approach.

What is the role of preliminary data in an Idea Development Award application?

Preliminary data serves as a feasibility anchor. The program encourages ambitious concepts, but expects enough real-world grounding to justify investment and to make it plausible the project can deliver interpretable results within the award period.

Is there a specific pathway for early-career investigators?

Yes. The opportunity includes a New Investigator category with a dedicated focus on early-career faculty.

Who qualifies as a New Investigator for this opportunity?

For FY21, the program explicitly encouraged applications from independent investigators within 10 years of their first faculty appointment (or an equivalent position). Applicants are responsible for documenting that they meet the eligibility criteria described in the opportunity’s eligibility section.

Do New Investigators compete directly against established investigators?

No. The New Investigator track is structured so that early-career applicants compete separately from established investigators. Peer review and programmatic review are conducted separately for the two groups.

Are collaborations required for New Investigators?

Collaborations are strongly encouraged. New Investigators are encouraged to collaborate with researchers who have established DMD expertise and/or complementary skills that strengthen the project.

What should a New Investigator application say about collaborations?

The application is expected to explain, in practical terms, how collaborations fill gaps in the principal investigator’s background and improve the project’s ability to answer the research question.

Who is the sponsoring agency and administering office for this award?

The award is offered by the Department of Defense and administered through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

What type of funding instrument is used (grant vs. cooperative agreement)?

Administratively, the opportunity could be issued as a cooperative agreement or a grant.

What CFDA number is associated with this opportunity?

The opportunity was listed under CFDA 12.420, described as "Science and Technology and other Research and Development."

Who is eligible to apply?

Eligibility was listed as unrestricted (open to any type of entity), with the note that applicants still needed to follow any clarifications provided in the full announcement text.

When was the opportunity posted and what was the closing date?

The opportunity was posted on May 27, 2021, and the original closing date was December 1, 2021.

How many awards did the program anticipate making?

The program anticipated making about eight awards.

What was the maximum award amount (award ceiling)?

The posted award ceiling was listed as 0 in the source record. This typically indicates applicants needed to refer to the full announcement for budget limits or that the ceiling was not specified in that particular data extract.

What is the overall takeaway for applicants considering this opportunity?

This award is best understood as a mechanism for launching daring but well-justified DMD research directions, supported by preliminary DMD-relevant data, with a distinct pathway for early-career faculty through a separate New Investigator competition that often benefits from strategic collaborations.